The Johns Hopkins Division of Pain Medicine offers safe, state of the art care to patients in pain by promoting strong clinical service, education and research.
Baltimore, MD
Joined October 2017
- Tweets419
- Following250
- Followers1.3K
- Likes417
Johns Hopkins Pain retweeted
Most preclinical CIPN studies use a single, compressed chemotherapy course, unlike repeated cycles in patients. Our new study, led by Ahmed O. Bakare, PhD, uses a repeated-cycle paclitaxel model and finds T cells play an important role in cold-evoked pain.
sciencedirect.com/science/ar…
ALT Study design showing T cell-competent and T cell-deficient rats receiving two paclitaxel treatment cycles separated by 10 weeks. Pain behaviors were assessed longitudinally, with DRG, sciatic nerve, and spleen collected for gene expression, immunohistochemistry, and flow cytometry.
Johns Hopkins Pain retweeted
Glad to see the September issue of @RAPMOnline focused on intrathecal drug delivery. Includes our practical guide to management and complications, plus a review of perioperative, obstetric, and ICU management of patients with implanted pumps.
rapm.bmj.com/content/51/9
Johns Hopkins Pain retweeted
A psychedelic compound best known for its effects on the brain may help prevent one of chemotherapy's most debilitating side effects—chemotherapy-induced peripheral neuropathy, researchers report in Science.
In mouse models, as few as two doses of psilocybin given before treatment durably prevented CIPN through multiple cycles of chemotherapy, while preserving both nerve function and the therapies’ tumor-killing effects.
📄: scim.ag/4ctTNaF
#SciencePerspective: scim.ag/466LJcj
Johns Hopkins Pain retweeted
Are complex regional pain syndrome types I and II the same? ovid.com/10.1097/j.pain.0000…
Johns Hopkins Pain retweeted
Excellent ACCM Grand Rounds by Daniel J. Clauw on #fibromyalgia and #nociplastic pain. Great discussion on central pain mechanisms, evidence-based therapies, and improving recognition of chronic pain conditions that remain widely misunderstood. #PainMedicine #PainResearch
Johns Hopkins Pain retweeted
Interesting comment on Chemokines and Pain from @ghasemloulab @PAINthejournal #neuroimmunology
journals.lww.com/pain/fullte…
Johns Hopkins Pain retweeted
🎙️ New RAPM Focus Podcast 50!
💊 Brian Sites, MD, Eric Schwenk, MD, and Kishor Gandhi, MD, discuss the pros and cons of perioperative gabapentinoids and why a nuanced, patient-specific approach matters.
🔗 rapmfocusbmj.podbean.com/e/e…
#RAPM #Anesthesiology #PainMedicine
Johns Hopkins Pain retweeted
asahq.org/faer/about/news-an…
The 40th anniversary fun continues with this latest article from FAER! Featuring words from past leaders like Drs. Patricia Kapur & James Eisenach, testimonials from #FAERgrantees like Drs. Sean Mackey & Sapna Kudchadkar, all bundled up with a look back at 40 years of FAER successes, give it a read @ the link!
#TheFutureIsFAER #FAERmsarf #FAERrsp #Anesthesiology #Research
Johns Hopkins Pain retweeted
Outstanding Grand Rounds with Dr. Michele Curatolo on human-centric molecular pain neuroscience. A rigorous, integrative framework linking pain neurobiology to clinical phenotypes and potential treatment strategies.
#PainResearch #Neuroscience #TranslationalMedicine
Johns Hopkins Pain retweeted
Honored to host ACCM Grand Rounds with Michele Curatolo, MD, PhD—a powerful reminder that pain is never “one thing,” but a complex, human experience shaped by timing, character, sensitivity, and context.
Thought-provoking science. Clinical relevance. Inspiring perspective.
Johns Hopkins Pain retweeted
Online ahead of print in Molecular Pain:
T cells shape paclitaxel-induced neuropathic pain in a modality- and phase-specific manner, with a selective role in cold hypersensitivity.
journals.sagepub.com/doi/abs…
Johns Hopkins Pain retweeted
Nearly 1 in 4 U.S. adults live with chronic pain. At Maimonides, we're proud to invest in patient-centered care that offers options beyond opioids. CNN's @drsanjaygupta features Dr. Sergey Motov & our ER team in It Doesn't Have to Hurt - Sept. 7, 9PM ET/PT.
@maimoems @pained
Johns Hopkins Pain retweeted
"Take the time to listen and validate your patients’ pain experiences. Learning how the pain affects their daily activities may more precisely direct therapy."- @DoctorSivaMD @HopkinsPain @HopkinsACCM @RAPMOnline #MedTwitter closler.org/lifelong-learnin…
Johns Hopkins Pain retweeted
Resiniferatoxin (RTX), a plant-derived compound, could pave the path for easing cancer-related pain. Recent NIH research shows that after a single injection of RTX, patients with advanced-stage cancer experienced a decrease in severe pain and the use of pain-relieving opioids.
Read more: go.nih.gov/fiMMo2Q.
ALT A fiery red pepper engulfed in flames against a dark background.
Johns Hopkins Pain retweeted
Chronic pain remains a major challenge—despite scientific progress, many patients still face delays, stigma, and limited options. I spoke with @Newsweek about why better science hasn’t always led to better care.
newsweek.com/2025/08/22/chro…
#ChronicPain #PainResearch #HealthPolicy
Johns Hopkins Pain retweeted
💊 Lost in conversion?
Converting intrathecal to oral opioids isn't as simple as 1:300.
This RAPM case report shows:
🧩 Real-life ratios = 1:2 to 1:12
⚠️ 1:300 may be dangerously outdated
🔗 doi.org/10.1136/rapm-2025-10…
By @talktoratan @DoctorSivaMD
#Opioids #RAPM
Johns Hopkins Pain retweeted
#regionalanesthesia #pain
@ASRA_Society Consensus Practice Infection Control guidelines: 👇🏿
Check out: rapm.bmj.com/content/early/2…
@DProvenzanoMD
Full article: rapm.bmj.com/content/early/2… @NarouzeMD @RAPMOnline @Ropivacaine @MayoPainMed @ESRA_Society @dr_tinadoshi @rakesh6282
Johns Hopkins Pain retweeted
It is unbelievable that when I started my lab 11 years ago people referred to itch as a "niche" therapeutic domain. Look at the monthly Rx of Ebglyss and Adbry (anti-IL-13 mAb) and Nemluvio (anti-IL-31RA mAb) since launch. Dupixent (anti-IL-4R mAb) is not on this chart because it's so far along.
Johns Hopkins Pain retweeted
Just arrived in my office-3rd edition of my book. New chapters, my original art, patient stories, and case studies. Available in September....#kathleensluka #slukaart #painscience @UIowaPTRS
@uihealthcare @IowaMed @UIowaNeuro
Johns Hopkins Pain retweeted
What do you think the next step will be in mechanism-based nonopioid analgesic #painmanagement? Zeng et al. review the challenges and breakthroughs, as well as the need for pharmacodynamically distinct multimodal interventions in @jclinicalinvest bit.ly/44cmzJ8 #PRF
